USO 23309
MK2870-012: A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) At Surgery
Disease Types: Breast Cancer Research
Eligibility Requirements:
• Centrally confirmed TNBC with non-pCR (ypT0/Tis ypN0) at surgery
• Neoadj tx based on KEYNOTE-522 (pembrolizumab with
carboplatin/taxanes and pembrolizumab with anthracycline-based
chemo) followed by surgery
• Completed ≥5 doses of neoadj pembro (or 3 doses if pembro was
given on q6 weeks schedule) + chemo, incl ≥1 dose of
anthracycline
• No evidence of locoregional or distant relapse
• Randomization within 16 weeks from surgical resection
• Prior PARPi excluded regardless of BRCA mutation status
• Adjuvant anticancer therapy excluded
• Adjuvant RT allowed, must be completed prior to randomization
• Prior tx with TROP2 ADC, ADC with topo I inhibitor, PD-(L)1, PD-L2
inhibitor, or agents directed to stimulatory or coinhibitory T-cell receptor
excluded.
• Prior pembro for neoadjuvant tx allowed
For more information on this trial CLICK HERE .
Available at:
- Chesapeake
- Hampton (CarePlex)
- Newport News (Port Warwick III)
- Norfolk (Brock Cancer Center)
- Virginia Beach (Princess Anne)
- Williamsburg